Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
Top Cited Papers
- 1 October 2006
- journal article
- research article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 55 (4), 598-606
- https://doi.org/10.1016/j.jaad.2006.05.027
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2005
- A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionBritish Journal of Dermatology, 2005
- Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodiesBMJ, 2005
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004
- Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failedAnnals Of The Rheumatic Diseases, 2004
- Etanercept as Monotherapy in Patients with PsoriasisNew England Journal of Medicine, 2003
- Changing paradigms in dermatology: tumor necrosis factor alpha (tnf-α) blockade in psoriasis and psoriatic arthritisClinics in Dermatology, 2003
- A systematic review of five systemic treatments for severe psoriasisBritish Journal of Dermatology, 1997
- Epidemiology of Psoriasis: Clinical Issues.Journal of Investigative Dermatology, 1994
- The Natural History of Psoriasis in 5,600 PatientsDermatology, 1974